INTUITIVE SURGICAL INC
TCW Concentrated Large Cap Growth Fund’s Q2 2026 letter cites Intuitive Surgical (NASDAQ:ISRG) amid near-term volatility. The fund says ISRG beat consensus on revenue and Da Vinci procedure growth, but China and Japan system placements disappointed. It notes 2.3M shares repurchased for $1.1B in 1Q26 and raised 2026 guidance. ISRG closed at $401.27 on July 20, 2026.
Intuitive Surgical (ISRG) faces new U.S. competition after Johnson & Johnson received FDA authorization for its Ottava robotic surgical system. J&J plans to pair Ottava with existing tools, potentially challenging Intuitive’s da Vinci installed base and recurring instrument and service revenue. Investors will watch Ottava placements and any impact on ISRG procedure growth.
GUTHART GARY S sold 10,000 indirectly-held shares of INTUITIVE SURGICAL INC (ISRG) at $400.00 ($4.00M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 12 news stories mentioning ISRG (INTUITIVE SURGICAL INC). Coverage has skewed bullish: 5 bullish, 5 neutral, and 2 bearish.
Recent ISRG coverage spans market movers, financial news and macro economy.
In the last 30 days, ISRG insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($4.4M). The most active reporter was Brosius Mark, EVP & Chief Mfg and Supply Cha, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The article frames ISRG as supported by Da Vinci 5 launch and raised 2026 guidance, while near-term risk is weaker international placements (China/Japan) and negative medtech sentiment.
FDA-authorized competition (Ottava) could increase tender and replacement-cycle pressure on ISRG’s da Vinci installed base, with potential downside to instrument/service recurring revenue if displacement occurs.
This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited signal value for near-term fundamentals.
Valuation sensitivity is driven by an as-yet-unquantified 2027 instrument pricing change tied to the extended use program, creating uncertainty around forward earnings and the multiple.
Upgrade-driven sentiment should improve near-term positioning, especially if investors accept the competition risk framing.
alphai scores every news story that mentions ISRG with an AI model for sentiment and relevance, and aggregates insider trades from INTUITIVE SURGICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
TCW Concentrated Large Cap Growth Fund’s Q2 2026 letter cites Intuitive Surgical (NASDAQ:ISRG) amid near-term volatility. The fund says ISRG beat consensus on revenue and Da Vinci procedure growth, but China and Japan system placements disappointed. It notes 2.3M shares repurchased for $1.1B in 1Q26 and raised 2026 guidance. ISRG closed at $401.27 on July 20, 2026.
6 min readIntuitive Surgical (ISRG) faces new U.S. competition after Johnson & Johnson received FDA authorization for its Ottava robotic surgical system. J&J plans to pair Ottava with existing tools, potentially challenging Intuitive’s da Vinci installed base and recurring instrument and service revenue. Investors will watch Ottava placements and any impact on ISRG procedure growth.
5 min readGUTHART GARY S sold 10,000 indirectly-held shares of INTUITIVE SURGICAL INC (ISRG) at $400.00 ($4.00M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readIntuitive Surgical (ISRG) is trading around $401.23, about 32% below its 52-week high and down 15% over 12 months versus a 22% S&P 500 gain. The stock trades at ~37.7x trailing adjusted earnings; analysts expect ~$12.08/share by 2027, implying ~33x. Forecast growth assumes margin give-back, while da Vinci placements rose 18% YoY in Q2 2026 and instrument pricing for 2027 is not finalized.
6 min readJim Cramer’s “top 10 things to watch” covers July CPI (headline 3.4% YoY, core 2.5%), with 2-year Treasury yields moving lower. He also cites stock moves and analyst actions: CoreWeave up ~19% on results, Super Micro target boosts to $39, Aramark target to $71, Cardinal Health target raised, Intuitive Surgical upgraded, Palo Alto Networks target to $415, Novo Nordisk downgraded, and On Holding removed after guidance cuts.
7 min readOppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform and set a $500 price target, citing its strategy to “crowd out” competitors. The note says U.S. rivals face workflow and real-estate issues and that Intuitive’s customized contracts and per-click model complicate returns. It flags international threats from Chinese platforms and expects robotic surgery to reach about 5.5M procedures by 2030.
3 min read24/7 Wall St. lists Wednesday analyst research calls. Upgrades include Hilton (HLT) to Buy with a $365 target, Intuitive Surgical (ISRG) to Outperform with a $500 target, Merck (MRK) to Outperform with a $143 target, and Okta (OKTA) to Outperform with a $170 target. Downgrades include The Gap (GAP) to Hold, and Novo Nordisk (NVO) to Hold. Initiations cover Genmab (GMAB) and Marriott (MAR).
6 min readInvesting.com reports Intuitive Surgical (ISRG) rose about 0.8% in pre-open after Oppenheimer upgraded it to Outperform from Perform and set a $500 price target. Oppenheimer and Bank of America Securities issued Buy ratings, citing da Vinci’s competitive position and Per Click Model. The article also notes ISRG Q2 2026 EPS of $2.80 vs $2.51 consensus.
4 min readIntuitive Surgical (ISRG) shares rose about 9% after the company reported fiscal Q2 2026 results that beat revenue and adjusted EPS forecasts. The article also notes ISRG updated bylaws to align shareholder voting and director nomination rules with SEC universal proxy requirements. Investors focused on moderating U.S. procedure growth and governance changes.
6 min readIntuitive Surgical (ISRG) reported fiscal Q2 2026 results that beat consensus, with revenue up 19% to $2.89B and adjusted EPS of $2.80, $0.30 above estimates. Shares fell as investors worried about slower domestic procedure growth. Worldwide procedures rose about 16%, and da Vinci and Ion grew ~15% and ~36%. UBS cut its price target to $500 from $550.
6 min read
